News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
268,219 Results
Type
Article (14267)
Company Profile (281)
Press Release (253671)
Multimedia
Podcasts (48)
Webinars (7)
Section
Business (79534)
Career Advice (152)
Deals (13231)
Drug Delivery (35)
Drug Development (50462)
Employer Resources (31)
FDA (5725)
Job Trends (5134)
News (144441)
Policy (10033)
Tag
Academia (915)
Accelerated approval (2)
Adcomms (12)
Allergies (52)
Alliances (21674)
ALS (64)
Alzheimer's disease (848)
Antibody-drug conjugate (ADC) (100)
Approvals (5752)
Artificial intelligence (125)
Autoimmune disease (18)
Automation (5)
Bankruptcy (105)
Best Places to Work (4559)
BIOSECURE Act (6)
Biosimilars (43)
Biotechnology (232)
Bladder cancer (59)
Brain cancer (20)
Breast cancer (155)
Cancer (1485)
Cardiovascular disease (117)
Career advice (133)
Career pathing (2)
CAR-T (118)
Cell therapy (333)
Cervical cancer (8)
Clinical research (41093)
Collaboration (542)
Compensation (263)
Complete response letters (13)
COVID-19 (1034)
CRISPR (42)
C-suite (165)
Cystic fibrosis (76)
Data (1531)
Denatured (11)
Depression (31)
Diabetes (139)
Diagnostics (1300)
Digital health (3)
Diversity (2)
Diversity, equity & inclusion (9)
Drug discovery (85)
Drug pricing (28)
Drug shortages (3)
Duchenne muscular dystrophy (90)
Earnings (29862)
Editorial (18)
Employer branding (4)
Employer resources (29)
Events (48629)
Executive appointments (464)
FDA (6432)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (498)
Gene editing (97)
Generative AI (10)
Gene therapy (255)
GLP-1 (367)
Government (1081)
Grass and pollen (2)
Guidances (27)
Healthcare (6594)
Huntington's disease (22)
IgA nephropathy (25)
Immunology and inflammation (92)
Indications (20)
Infectious disease (1099)
Inflammatory bowel disease (115)
Inflation Reduction Act (8)
Influenza (19)
Intellectual property (67)
Interviews (17)
IPO (7275)
IRA (11)
Job creations (861)
Job search strategy (127)
Kidney cancer (7)
Labor market (5)
Layoffs (211)
Leadership (3)
Legal (1386)
Liver cancer (33)
Lung cancer (205)
Lymphoma (102)
Machine learning (3)
Management (7)
Manufacturing (140)
MASH (54)
Medical device (2604)
Medtech (2605)
Mergers & acquisitions (6288)
Metabolic disorders (391)
Multiple sclerosis (53)
NASH (13)
Neurodegenerative disease (68)
Neuropsychiatric disorders (25)
Neuroscience (1260)
NextGen: Class of 2025 (2017)
Non-profit (852)
Now hiring (21)
Obesity (194)
Opinion (102)
Ovarian cancer (63)
Pain (44)
Pancreatic cancer (56)
Parkinson's disease (121)
Partnered (8)
Patents (130)
Patient recruitment (79)
Peanut (35)
People (25654)
Pharmaceutical (47)
Pharmacy benefit managers (5)
Phase I (14518)
Phase II (19113)
Phase III (12082)
Pipeline (818)
Policy (46)
Postmarket research (852)
Preclinical (6141)
Press Release (30)
Prostate cancer (62)
Psychedelics (35)
Radiopharmaceuticals (213)
Rare diseases (292)
Real estate (1419)
Recruiting (12)
Regulatory (8650)
Reports (15)
Research institute (938)
Resumes & cover letters (17)
Rett syndrome (4)
RNA editing (5)
RSV (10)
Schizophrenia (61)
Series A (98)
Series B (63)
Service/supplier (1)
Sickle cell disease (40)
Special edition (11)
Spinal muscular atrophy (117)
Sponsored (12)
Startups (1975)
State (1)
Stomach cancer (4)
Supply chain (23)
Tariffs (9)
The Weekly (36)
Vaccines (215)
Venture capitalists (32)
Weight loss (110)
Women's health (15)
Worklife (2)
Date
Today (12)
Last 7 days (519)
Last 30 days (1470)
Last 365 days (19452)
2025 (6361)
2024 (20553)
2023 (22414)
2022 (26825)
2021 (27807)
2020 (23357)
2019 (16223)
2018 (11740)
2017 (13746)
2016 (11841)
2015 (14352)
2014 (10393)
2013 (7484)
2012 (7532)
2011 (7616)
2010 (7432)
Location
Africa (148)
Alabama (42)
Alaska (2)
Arizona (53)
Arkansas (5)
Asia (17319)
Australia (2935)
California (3890)
Canada (1145)
China (361)
Colorado (149)
Connecticut (152)
Delaware (103)
Europe (37262)
Florida (468)
Georgia (117)
Idaho (16)
Illinois (234)
India (10)
Indiana (92)
Iowa (2)
Japan (75)
Kansas (62)
Kentucky (5)
Louisiana (3)
Maine (11)
Maryland (478)
Massachusetts (3095)
Michigan (70)
Minnesota (145)
Mississippi (1)
Missouri (24)
Montana (14)
Nebraska (4)
Nevada (17)
New Hampshire (14)
New Jersey (971)
New Mexico (12)
New York (1050)
North Carolina (556)
North Dakota (5)
Northern California (1716)
Ohio (112)
Oklahoma (9)
Oregon (21)
Pennsylvania (743)
Puerto Rico (6)
Rhode Island (19)
South America (208)
South Carolina (4)
Southern California (1498)
Tennessee (25)
Texas (450)
United States (13337)
Utah (53)
Virginia (80)
Washington D.C. (30)
Washington State (352)
Wisconsin (15)
268,219 Results for "nanoscope therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Lone Star Bio
Nanoscope Therapeutics to Present at the BIO International Convention - May 29, 2024
Nanoscope Therapeutics Inc today announced that management will present at the BIO International Convention, taking place June 3-6, 2024, in San Diego, California.
May 29, 2024
·
1 min read
Lone Star Bio
Nanoscope Therapeutics to Participate in the 2024 Leerink Partners Biopharma Private Company Connect
Nanoscope Therapeutics Inc. today announced that management will participate in one-on-one meetings with investors at the 2024 Leerink Partners Biopharma Private Company Connect, being held virtually on June 25-26, 2024.
June 18, 2024
·
1 min read
Lone Star Bio
Nanoscope Therapeutics Announces Participation in Upcoming Conferences - February 21, 2024
Nanoscope Therapeutics Inc. today announced that Sulagna Bhattacharya , Chief Executive Officer of Nanoscope Therapeutics, and other members of its senior management team will participate in two upcoming conferences.
February 21, 2024
·
2 min read
Lone Star Bio
Nanoscope Therapeutics to Present at the OIS and Retinal Cell and Gene Therapy Innovation Summits
Nanoscope Therapeutics Inc. today announced that Samarendra Mohanty , PhD, Co-Founder, and President, will present in the Retinal Cell and Gene Therapy Innovation Summit 2024.
April 29, 2024
·
2 min read
Business
Nanoscope Therapeutics Appoints Khandan Baradaran as Senior Vice President of Regulatory and Quality
Nanoscope Therapeutics Inc., a late-stage clinical biotechnology company developing gene therapies for inherited retinal diseases and age-related macular degenerations, announced the appointment of Khandan Baradaran, PhD, as Senior Vice President of Regulatory and Quality.
May 14, 2024
·
2 min read
Lone Star Bio
Nanoscope Therapeutics to Present at the World Orphan Drug Congress 2024
Nanoscope Therapeutics Inc. today announced that Sulagna Bhattacharya , Chief Executive Officer and Samarendra Mohanty, PhD, President and Chief Scientific Officer will present and participate in a panel discussion at the World Orphan Drug Congress 2024, taking place from April 23-25, 2024 in Boston, Massachusetts.
April 17, 2024
·
2 min read
Lone Star Bio
Nanoscope Therapeutics Announces Presentations in Upcoming ASGCT Annual Meeting and Retina World Congress
Nanoscope Therapeutics Inc. announced that its viral and laser-delivered Multi-Characteristic Opsin gene therapy platforms will be featured in multiple presentations at the 2024 ASGCT Annual Meeting and the Retina World Congress, being held in Baltimore, Maryland and Fort Lauderdale, Florida, respectively, in May.
May 7, 2024
·
3 min read
Business
Nanoscope Therapeutics Enhances Mutation-Independent Retinal Gene Therapy Programs with Appointment of Allen C. Ho, MD, as Chief Medical Advisor
Nanoscope Therapeutics, Inc. announced today the appointment of Allen C. Ho , MD, FACS, FASRS, as Chief Medical Advisor, where he will help define the strategy of developing the gene mutation-agnostic therapies.
April 25, 2024
·
3 min read
Lone Star Bio
Nanoscope Therapeutics Provides Regulatory Update on MCO-010 for the Treatment of Retinitis Pigmentosa
Nanoscope Therapeutics Inc. today provided an update following recent regulatory discussions with the U.S. Food and Drug Administration (“FDA”) and from the Scientific Advice meeting with the Icelandic Medicines Agency (“IMA”), regarding the regulatory path of MCO-010 for the treatment of RP.
January 18, 2024
·
4 min read
Drug Development
Nanoscope Claims Phase II Win for Gene Therapy After Changing Primary Endpoint
Nanoscope Therapeutics nabbed a victory on the changed primary endpoint of its Phase IIb vision loss gene therapy trial Tuesday, teeing the biotech up to file for FDA approval of the candidate this year.
March 27, 2024
·
2 min read
·
Nick Paul Taylor
1 of 26,822
Next
